After successful angioplasty, eligible individuals are divided into two groups: one continues taking riociguat and the other stops the medication. Both groups are followed for at least twelve months, with regular clinic visits to monitor health status. Simple tests include a walking test that measures how far a person can walk in six minutes (6‑minute walk distance) and questionnaires that assess daily functioning and quality of life, such as the EQ-5D-5L and disease‑specific EmPHasis‑10. Blood tests for a heart‑stress marker (NT-proBNP) and routine checks of heart function are also performed.

During the follow‑up period, any serious events such as death, hospitalization because of worsening lung pressure, right heart failure, need for a lung transplant, use of intravenous diuretics or inotropic support, or requirement of medication called prostanoids are recorded. The study aims to provide information on whether stopping riociguat after a successful procedure is safe or if continuing the medication offers better protection against these serious outcomes.

The purpose of the study is to evaluate how much of the test agent is taken up by the heart tissue in these conditions. After the injection, a PET scan (a type of picture that shows where a radioactive substance goes inside the body) is performed to see the distribution of the agent in the heart muscle or valve areas. Some participants with suspected disease may have a second scan after receiving standard anti‑inflammatory treatment, while healthy volunteers undergo a single scan to understand normal distribution and safety.

The main aim of the study is to compare how each approach affects body weight after six months.

Participants will be assigned by chance to one of the treatment groups and will follow the assigned plan for up to one year. Throughout the study, regular visits will be scheduled to record weight, check blood pressure, cholesterol levels, and blood sugar, and to monitor any side effects. The study does not involve any invasive procedures, and all information is collected in a routine clinical setting.

The purpose of the study is to determine whether surgery or the injection provides better overall results, including reduction in size of the lesion, scar quality, and lip symmetry, after one year.

Participants are randomly assigned to either the surgical group or the injection group and are followed for 12 months. After the chosen procedure, follow‑up visits occur at regular intervals to take photographs, complete questionnaires, and record any pain using a rating system called the visual analog scale, where 0 means no pain and 10 means the worst pain. An imaging test known as MRI is used to measure the size of the lesion, and blood samples are taken to check clotting factors such as D-dimer and fibrinogen. Pain diaries and satisfaction surveys are also collected throughout the study period.

The investigation tests a new oral medication called MK-7262 alone and in combination with a second oral agent, enlicitide decanoate. The goal is to see whether these medicines can lower the amount of the protein and the bad cholesterol more than a dummy pill (placebo).

Participants will take the assigned tablets once daily for several weeks, with regular check‑ins at the clinic to collect blood samples and report any side effects. The study lasts about two months, after which safety and how well the medicines worked are assessed.

The purpose of the study is to determine whether taking ticagrelor alone is as safe and effective as the standard two‑medicine regimen in preventing serious bleeding and major heart problems over one year. Participants are randomly assigned to one of the two groups and take the assigned tablets daily for twelve months, with routine check‑ups scheduled throughout the year to monitor health and any side effects.

Researchers will look at two main outcomes: first, any bleeding events classified by the Bleeding Academic Research Consortium as type 2, 3, or 5, which represent moderate to severe bleeding; and second, a combined measure that includes death from any cause, another heart attack, stroke, or the need for a procedure to open blocked heart arteries (coronary revascularization). Information on these events will be collected during the scheduled visits and recorded for analysis.

Participants will be randomly assigned to receive either the study drug at one of three dose levels or the placebo, and neither the participants nor the study staff will know which treatment is given. Over the course of several weeks, blood samples will be taken to assess clotting using tests such as aPTT (a test that measures how quickly blood forms a clot) and PT/INR (another test that evaluates clotting time). Heart health will be checked with a 12-lead ECG (a recording of the heart’s electrical activity). Safety will be monitored by recording any side effects, reviewing laboratory results, vital signs, and physical examinations.

During the 24‑week period, participants are randomly assigned to one of the two groups and neither the participants nor the study staff know which treatment is given (double‑blind). Regular visits include blood tests that measure NT-proBNP, a protein that rises when the heart is under stress, and imaging tests such as an ultrasound of the heart (echocardiogram) that assess measurements like left ventricular end-diastolic volume index, left ventricular end-systolic volume index, E/e′ ratio, global longitudinal strain and left atrial volume index. Participants also complete the Kansas City cardiomyopathy questionnaire to report symptoms and quality of life, and a routine 12‑lead Electrocardiogram is performed to check the heart’s electrical activity. Throughout the study, safety is monitored by recording any side effects and checking routine laboratory values.

Participants will take the assigned medication for about three months. Their heart rhythm will be recorded using a portable device called a Holter-ECG, which continuously monitors the heart’s electrical activity for a week at the start of the study and again after three months. In addition, participants will answer simple questionnaires that measure overall well‑being, including the EQ-5D visual scale and the SF-12 health survey, to see how the treatment impacts daily life.

Throughout the study, any side effects such as fatigue, dizziness, low blood pressure, or more serious heart problems will be recorded. The need for additional procedures, such as a catheter-based technique to destroy the source of the extra beats, will also be noted. The overall goal is to find the safer and more effective option for managing these premature heartbeats.